Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection (Q35917447)

11 August 2017

1 reference

title

Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection (English)

1 reference

11 August 2017

1 reference

1 reference

1 reference

Stephanos J Hadziyannis

series ordinal

1

1 reference

PubMed ID

15482214

11 August 2017

George V Papatheodoridis

series ordinal

2

1 reference

11 August 2017

1 August 2004

1 reference

Expert Review of Anti-infective Therapy

11 August 2017

1 reference

11 August 2017

2

1 reference

11 August 2017

475-483

1 reference

11 August 2017

4

1 reference

Management of hepatitis B: 2000--summary of a workshop

11 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Review article: current management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Hepatitis B virus: old, new and future approaches to antiviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Adefovir dipivoxil: a review of its use in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Comparative effects of adefovir and selected nucleoside inhibitors of hepatitis B virus DNA polymerase on mitochondrial DNA in liver and skeletal muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Treatment of HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Adefovir dipivoxil as a treatment for hepatic failure caused by lamivudine-resistant HBV strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Tenofovir treatment in an unselected cohort of highly antiretroviral experienced HIV positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Management of hepatitis B in patients coinfected with the human immunodeficiency virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Suppressing hepatitis B without resistance--so far, so good

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.4.475

21 January 2018

Identifiers

DOI

10.1586/14787210.2.4.475

1 reference

11 August 2017

1 reference

PubMed ID

15482214